Treatment of IgM-associated immunoglobulin light-chain amyloidosis with rituximab-bendamustine

Blood. 2018 Aug 16;132(7):761-764. doi: 10.1182/blood-2018-04-846493. Epub 2018 Jun 20.
No abstract available

Publication types

  • Letter

MeSH terms

  • Aged
  • Aged, 80 and over
  • Bendamustine Hydrochloride / administration & dosage*
  • Disease-Free Survival
  • Female
  • Humans
  • Immunoglobulin Light-chain Amyloidosis / drug therapy*
  • Immunoglobulin Light-chain Amyloidosis / mortality*
  • Immunoglobulin M*
  • Male
  • Middle Aged
  • Rituximab / administration & dosage*
  • Survival Rate

Substances

  • Immunoglobulin M
  • Rituximab
  • Bendamustine Hydrochloride